DASLEMIA 50MG TABLET

About

Daslemia 50mg Tablet contains Dasatinib, a potent oral tyrosine kinase inhibitor (TKI) used in the treatment of certain types of leukemia. It works by selectively blocking the activity of several tyrosine kinases, including BCR-ABL, SRC family kinases, and others, which are crucial for the growth and survival of cancer cells in chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). By inhibiting these enzymes, Dasatinib effectively prevents the proliferation of cancerous cells and induces their apoptosis. This targeted therapy offers a significant advantage in managing these hematological malignancies, particularly in patients who are resistant or intolerant to other treatments like imatinib. Close monitoring for efficacy and potential side effects is essential throughout the treatment course.

Uses

• Treatment of chronic myeloid leukemia (CML)
• Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)
• Used in patients resistant or intolerant to prior therapy
• Effective in both chronic and accelerated phases of CML

Directions For Use

Take orally once daily with or without food, as directed by your physician. Do not crush, cut, or chew the tablets.

Benefits

• Targets specific cancer-promoting pathways
• Effective in imatinib-resistant CML and Ph+ ALL
• Improves remission rates in eligible patients
• Oral administration for convenience
• Can be used in various phases of CML
• Reduces proliferation of leukemia cells

Side Effects

• Fluid retention (e.g., pleural effusion, edema)
• Myelosuppression (anemia, neutropenia, thrombocytopenia)
• Diarrhea
• Headache
• Fatigue
• Nausea
• Rash
• Bleeding events
• Shortness of breath
• Abdominal pain
• Muscle pain
• QT prolongation

Safety Measures

• Alcohol - Avoid or limit alcohol consumption as it may exacerbate gastrointestinal side effects or increase liver strain.
• Pregnancy - Contraindicated during pregnancy due to potential for fetal harm. Women of childbearing potential must use effective contraception.
• Breastfeeding - Contraindicated during breastfeeding as it is unknown if dasatinib is excreted in human milk, but potential for serious adverse reactions in infants exists.
• Liver - Use with caution in patients with liver conditions; dosage adjustment may be necessary in hepatic impairment.
• Kidney - Use with caution in patients with kidney conditions; close monitoring is advised, though specific dose adjustments are not always required for mild to moderate impairment.
• Lung - Monitor for pulmonary arterial hypertension (PAH) and pleural effusion; report any new or worsening respiratory symptoms promptly.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.